Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Net Margin (2017 - 2025)

Historic Net Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 16.23%.

  • Puma Biotechnology's Net Margin fell 89900.0% to 16.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.11%, marking a year-over-year increase of 45600.0%. This contributed to the annual value of 10.07% for FY2024, which is 9000.0% up from last year.
  • As of Q3 2025, Puma Biotechnology's Net Margin stood at 16.23%, which was down 89900.0% from 11.17% recorded in Q2 2025.
  • Puma Biotechnology's Net Margin's 5-year high stood at 25.23% during Q3 2024, with a 5-year trough of 96.6% in Q3 2021.
  • For the 5-year period, Puma Biotechnology's Net Margin averaged around 0.66%, with its median value being 6.46% (2025).
  • As far as peak fluctuations go, Puma Biotechnology's Net Margin plummeted by -346100bps in 2021, and later soared by 959700bps in 2022.
  • Quarter analysis of 5 years shows Puma Biotechnology's Net Margin stood at 7.63% in 2021, then tumbled by -184bps to 6.4% in 2022, then surged by 366bps to 17.0% in 2023, then grew by 22bps to 20.7% in 2024, then fell by -22bps to 16.23% in 2025.
  • Its last three reported values are 16.23% in Q3 2025, 11.17% for Q2 2025, and 6.46% during Q1 2025.